MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease

Phase 1
Completed
Conditions
Sickle Cell Disease
First Posted Date
2013-07-11
Last Posted Date
2014-12-03
Lead Sponsor
Duke University
Target Recruit Count
5
Registration Number
NCT01895998
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

Phase 1
Completed
Conditions
Pompe Disease
Interventions
Drug: Placebo
Drug: Albuterol
First Posted Date
2013-06-25
Last Posted Date
2019-07-15
Lead Sponsor
Duke University
Target Recruit Count
16
Registration Number
NCT01885936
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

Not Applicable
Completed
Conditions
Cystic Fibrosis
Healthy
Interventions
Drug: Albuterol
Drug: Placebo saline
First Posted Date
2013-06-19
Last Posted Date
2023-11-29
Lead Sponsor
University of Arizona
Target Recruit Count
32
Registration Number
NCT01880723
Locations
🇺🇸

Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona, Tucson, Arizona, United States

Albuterol in Individuals With Late Onset Pompe Disease (LOPD)

Phase 1
Completed
Conditions
Pompe Disease
Interventions
First Posted Date
2013-05-22
Last Posted Date
2019-07-05
Lead Sponsor
Duke University
Target Recruit Count
8
Registration Number
NCT01859624
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Lung Function Changes of Induced Asthma Children Treated With Inhaled MgSO4

Not Applicable
Completed
Conditions
Asthma
Interventions
Drug: Magnesium Sulfate
Drug: magnesium sulfate & albuterol
Drug: Albuterol
First Posted Date
2013-05-20
Last Posted Date
2013-05-20
Lead Sponsor
Chongqing Medical University
Target Recruit Count
330
Registration Number
NCT01856959
Locations
🇨🇳

Center of Respiratory Disorders,Children's Hospital,Chongqing Medical University, Chongqing, Chongqing, China

Lung Function of Asthmatic Children by Nebulized MgSO4

Not Applicable
Completed
Conditions
Asthma
Interventions
Drug: Magnesium Sulfate & albuterol
Drug: albuterol
Drug: magnesium
First Posted Date
2013-02-26
Last Posted Date
2013-05-21
Lead Sponsor
Chongqing Medical University
Target Recruit Count
90
Registration Number
NCT01799109
Locations
🇨🇳

Center of Respiratory Disorders,Children's Hospital,Chongqing medical university, Chongqing, Chongqing, China

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: FS MDPI
Drug: Fp MDPI
Drug: Advair Diskus
Drug: Albuterol
First Posted Date
2013-01-21
Last Posted Date
2017-06-12
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
72
Registration Number
NCT01772368
Locations
🇺🇸

Teva Investigational Site 10456, San Antonio, Texas, United States

🇺🇸

Teva Investigational Site 10453, Denver, Colorado, United States

🇺🇸

Teva Investigational Site 10454, Skillman, New Jersey, United States

and more 7 locations

Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4
Completed
Conditions
HEALTHY SUBJECTS
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
ASTHMA
Interventions
First Posted Date
2012-11-04
Last Posted Date
2023-03-06
Lead Sponsor
Imperial College London
Target Recruit Count
65
Registration Number
NCT01721291
Locations
🇬🇧

Royal Brompton Hospital & Imperial College London, London, United Kingdom

Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2012-09-18
Last Posted Date
2018-06-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
261
Registration Number
NCT01687296
Locations
🇨🇳

GSK Investigational Site, Wuxi, China

Effect of the Salbutamol on Mechanical Properties of Respiratory System

Not Applicable
Conditions
Smoking
Airway Obstruction
Interventions
First Posted Date
2012-01-30
Last Posted Date
2012-02-02
Lead Sponsor
Rio de Janeiro State University
Target Recruit Count
200
Registration Number
NCT01521572
Locations
🇧🇷

Laboratory biomedical instrumentation - State University of Rio de Janeiro, Rio de Janeiro, Brazil

© Copyright 2025. All Rights Reserved by MedPath